Serum Ferritin in Healthy Women and Breast Cancer Patients

Serum Ferritin in Healthy Women and Breast Cancer PatientsSerum tumor markers are important tools in managing patients with breast cancer. Currently used CA 15-3 and CEA have found their clinical application particularly in the follow-up of patients with advanced disease. Ferritin belongs to a group of other molecules of potential interest to clinicians whose concentration is also altered in sera of patients with breast tumors. In this study the serum ferritin concentration was estimated in the sera of breast cancer patients before initial surgical treatment or those with advanced disease, and compared to healthy women as control. Ferritin level was measured by an immunoradiometric assay. The aim was to asses whether the serum ferritin concentration was altered in breast cancer and whether it could be related to progression of the disease. In healthy women, a statistically significant difference (p<0.05) in ferritin concentration was observed between premenopausal and postmenopausal women. In both breast cancer groups ferritin levels were higher than in healthy premenopausal women (both p<0.05). In patients with advanced disease, ferritin was further elevated (p<0.05) compared to preoperative levels in the patient group undergoing initial surgical treatment. These results indicate that an elevated ferritin concentration in the serum of younger women could serve as an additional parameter in breast cancer diagnosis and staging.

Download Full-text

A comparative study of selenium concentration and glutathione peroxidase activity in normal and breast cancer patients

Public Health Nutrition ◽

10.1017/s1368980008001924 ◽

2009 ◽

Vol 12 (1) ◽

pp. 59-63 ◽

Cited By ~ 11

Author(s):

Masoumeh Moradi ◽

Mohammad Hassan Eftekhari ◽

Abdolrasoul Talei ◽

Abdolreza Rajaei Fard

Keyword(s):

Breast Cancer ◽

Glutathione Peroxidase ◽

Cancer Patients ◽

Selenium Concentration ◽

Atomic Absorption Spectrophotometry ◽

Breast Cancer Patients ◽

Healthy Women ◽

Significant Difference ◽

Gpx Activity ◽

Control Study

AbstractObjectiveThe present study was undertaken to compare plasma Se values and glutathione peroxidase (GPX) activity in normal and breast cancer patients.DesignIn a case–control study, forty-five breast cancer patients and the same number of healthy women were randomly selected from their population. Se was measured in plasma by atomic absorption spectrophotometry and GPX activity in erythrocytes was measured using a standard spectrophotometric method.ResultsPlasma Se concentration in healthy women and breast cancer patients was in the normal range, with no statistically significant difference observed between the two groups (138·40 (sd 40·36) μg/l v. 132·15 (sd 35·37) μg/l, respectively). Erythrocyte GPX activity was significantly (P<0·01) higher in breast cancer patients (24·81 (sd 11·66) U/g Hb) compared with healthy women (20·29 (sd 4·24) U/g Hb).ConclusionThe present study indicated that Se deficiency was not a problem in the participants, and sufficient quantity of this element could increase GPX activity to have a protective effect against oxidative damage.

Download Full-text

Breast Cancer in the Young Patient

The American Surgeon ◽

10.1177/000313481007601226 ◽

2010 ◽

Vol 76 (12) ◽

pp. 1397-1400 ◽

Cited By ~ 25

Author(s):

Jack Sariego

Keyword(s):

Breast Cancer ◽

Young Patient ◽

Cancer Patients ◽

Advanced Disease ◽

Disease Stage ◽

Breast Cancer Patients ◽

Older Population ◽

Younger Patients ◽

Aggressive Disease ◽

Significant Difference

Patients under 40 years of age comprise about 5 per cent of the overall breast cancer population. These patients are often considered to have a more aggressive disease and are often treated differently as well. A review was performed of all breast cancer patients reported in the American College of Surgeons Cancer Database from 1998 to 2005. The study cohort included all patients less than 40 years of age. Data collected included stage at time of diagnosis, histologic type, and initial treatment performed. These data were then compared with those of patients age 40 or older. The 70,437 cohort patients identified comprised 5.0 per cent of all breast cancer patients reported. There was a statistically significant difference in stage at the time of presentation: 20 per cent of younger patients presented with advanced disease (stage III or IV) versus 13.5 per cent of older patients. A significantly greater percentage of younger patients also presented with infiltrating ductal carcinoma as opposed to the older population (76.9% vs 67.9%). A significantly greater percentage of young patients was treated with mastectomy when compared with the older population (47.7% vs 36.7%, respectively). This difference persisted even when data were controlled for stage. The younger breast cancer patient presents with more advanced disease, suggesting either a more aggressive disease or a greater delay in diagnosis. Also, at all stages, the young patient tends to be treated more “aggressively” surgically, suggesting that the prevailing concept that breast cancer is a “worse” disease in the young may be directing treatment options and patient choices.

Download Full-text

A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djz105 ◽

2019 ◽

Vol 111 (9) ◽

pp. 903-915 ◽

Cited By ~ 2

Author(s):

Yu Gui ◽

Xunzhou Liu ◽

Xianchun Chen ◽

Xi Yang ◽

Shichao Li ◽

...

Keyword(s):

Breast Cancer ◽

Surgical Treatment ◽

Cancer Patients ◽

Early Breast Cancer ◽

Statistical Tests ◽

Meta Analysis ◽

Axillary Node ◽

Survival Outcomes ◽

Breast Cancer Patients ◽

Significant Difference

Abstract Background In early breast cancer treatment, the preferred surgical regimen remains a topic of controversy, and conventional pairwise meta-analysis cannot provide a hierarchy based on clinical trial evidence. Therefore, a network meta-analysis was performed both for direct and indirect comparisons and to assess the survival outcomes of surgical regimens. Methods Randomized clinical trials comparing different surgical regimens for the treatment of early breast cancer were identified. Overall survival (OS) and disease-free-survival (DFS) were analyzed using random-effects network meta-analysis on the hazard ratio (HR) scale and calculated as combined HRs and 95% confidence intervals (CIs). All statistical tests were two-sided. Results The network meta-analysis compared 11 different surgical regimens that consisted of 13 and 17 direct comparisons between strategies for OS (34 trials; n = 23 587 patients) and DFS (32 trials; n = 22 552 patients), respectively. The values of surface under the cumulative ranking for OS and DFS after mastectomy (M)+radiotherapy (RT) were observed to be the largest. Breast-conserving surgery (BCS)+axillary node sampling+RT almost achieved the threshold for inferiority compared with the other surgical treatment arms and was statistically significantly associated with worse OS (HR = 0.51, 95% CI = 0.24 to 0.94; HR = 0.48, 95% CI = 0.22 to 0.92; HR = 0.51, 95% CI = 0.23 to 0.96). No statistically significant difference between BCS+sentinel lymph node biopsy (SLNB)+RT vs BCS+SLNB+intraoperative RT was observed in carrying out network meta-analysis (HR = 0.95, 95% CI = 0.64 to 1.36). Conclusions M+RT is safer than other surgical regimens for the treatment of early breast cancer patients because of the favorable balance between the survival outcomes. Early breast cancer patients who receive BCS should be given SLNB and not axillary node sampling. Intraoperative RT is no better than postoperative RT in patients who receive SLNB.

Download Full-text

CHANGES IN THE NIPPLE-AREOLA COMPLEX IN PATIENTS WITH BREAST CANCER

Problems in oncology ◽

10.37469/0507-3758-2017-63-4-593-597 ◽

2017 ◽

Vol 63 (4) ◽

pp. 593-597

Author(s):

Aziz Zikiryakhodzhaev ◽

Nadezhda Volchenko ◽

Erik Saribekyan ◽

Yelena Rasskazova

Keyword(s):

Breast Cancer ◽

Surgical Treatment ◽

Cancer Patients ◽

Molecular Subtypes ◽

Breast Cancer Patients ◽

Nipple Areola Complex ◽

Histological Types ◽

Areola Complex

The article presents data about the lesion of the nipple-areola complex in breast cancer. In 2015-2016 surgical treatment was performed in 101 breast cancer patients, different in size but with the mandatory removal of the nipple-areola complex. There are analyzed the dependence of the lesion of the nipple-areola complex from histological types of breast cancer, molecular subtypes, multicentricity, the location of tumor in the breast. The most significant criterion was the dependence of the lesion of the nipple-areola complex from the distance between tumor node and the nipple.

Download Full-text

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽

10.1186/s12885-021-08197-6 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Safa Najafi ◽

Maryam Ansari ◽

Vahid Kaveh ◽

Shahpar Haghighat

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Single Dose ◽

Side Effects ◽

Randomized Clinical Trial ◽

Cancer Patients ◽

Injection Site Reaction ◽

Study Groups ◽

Breast Cancer Patients ◽

Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

Download Full-text

Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients

Scientific Reports ◽

10.1038/s41598-021-87897-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Carlos Henrique F. Peiró ◽

Matheus M. Perez ◽

Glauco S. A. de Aquino ◽

Jéssica F. A. Encinas ◽

Luiz Vinícius de A. Sousa ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Glucose Transporter ◽

Carbonic Anhydrases ◽

Breast Cancer Patients ◽

Gene Expressions ◽

Liquid Biopsies ◽

Healthy Women ◽

Diagnostic Potential ◽

Laboratory Tool

AbstractIn tumor cells, higher expression of glucose transporter proteins (GLUT) and carbonic anhydrases (CAIX) genes is influenced by hypoxia-induced factors (HIF).Thus, we aimed to study the expression profile of these markers in sequential peripheral blood collections performed in breast cancer patients in order to verify their predictive potential in liquid biopsies. Gene expressions were analyzed by qPCR in tumor and blood samples from 125 patients and 25 healthy women. Differential expression was determined by the 2(−ΔCq) method. Expression of HIF-1α and GLUT1 in the blood of breast cancer patients is significantly higher (90–91 and 160–161 fold increased expression, respectively; p < 0.0001) than that found in healthy women. Their diagnostic power was confirmed by ROC curve. CAIX is also more expressed in breast cancer women blood, but its expression was detected only in a few samples. But none of these genes could be considered predictive markers. Therefore, evaluation of the expression of HIF-1α and GLUT1 in blood may be a useful laboratory tool to complement the diagnosis of breast cancer, in addition to being useful for follow-up of patients and of women with a family history of breast cancer.

Download Full-text

Erratum to: Content of HLA-G+ T Cells in the Peripheral Blood from Healthy Women and Breast Cancer Patients

Bulletin of Experimental Biology and Medicine ◽

10.1007/s10517-016-3224-6 ◽

2016 ◽

Vol 160 (4) ◽

pp. 592-592

Author(s):

E. O. Ostapchuk ◽

Yu. V. Perfil’eva ◽

Sh. Zh. Talaeva ◽

N. A. Omarbaeva ◽

N. N. Belyaev

Keyword(s):

Breast Cancer ◽

T Cells ◽

Cancer Patients ◽

Peripheral Blood ◽

Breast Cancer Patients ◽

Healthy Women

Download Full-text

Relationship Between Obesity and Pathologic Response to Neoadjuvant Chemotherapy Among Women With Operable Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2007.14.4527 ◽

2008 ◽

Vol 26 (25) ◽

pp. 4072-4077 ◽

Cited By ~ 106

Author(s):

Jennifer K. Litton ◽

Ana M. Gonzalez-Angulo ◽

Carla L. Warneke ◽

Aman U. Buzdar ◽

Shu-Wan Kau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Pathologic Complete Response ◽

Operable Breast Cancer ◽

Obese Patients ◽

Breast Cancer Patients ◽

Significant Difference ◽

Response To Neoadjuvant Chemotherapy

Purpose To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer. Patients and Methods From May 1990 to July 2004, 1,169 patients were diagnosed with invasive breast cancer at M. D. Anderson Cancer Center and received NC before surgery. Patients were categorized as obese (BMI ≥ 30 kg/m2), overweight (BMI of 25 to < 30 kg/m2), or normal/underweight (BMI < 25 kg/m2). Logistic regression was used to examine associations between BMI and pathologic complete response (pCR). Breast cancer–specific, progression-free, and overall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regression analysis. All statistical tests were two-sided. Results Median age was 50 years; 30% of patients were obese, 32% were overweight, and 38% were normal or underweight. In multivariate analysis, there was no significant difference in pCR for obese compared with normal weight patients (odds ratio [OR] = 0.78; 95% CI, 0.49 to 1.26). Overweight and the combination of overweight and obese patients were significantly less likely to have a pCR (OR = 0.59; 95% CI, 0.37 to 0.95; and OR = 0.67; 95% CI, 0.45 to 0.99, respectively). Obese patients were more likely to have hormone-negative tumors (P < .01), stage III tumors (P < .01), and worse overall survival (P = .006) at a median follow-up time of 4.1 years. Conclusion Higher BMI was associated with worse pCR to NC. In addition, its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancer patients.

Download Full-text

Exploring The Clinical Significance of Serum Angiopoietin-2 In Breast Cancer Patients

QJM ◽

10.1093/qjmed/hcab091.014 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Abeer I Abd Elmagid ◽

Hala Abdel Al ◽

Wessam El Sayed Saad ◽

Seham Kamal Mohamed

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Serum Levels ◽

Tnm Staging ◽

Control Group ◽

Healthy Controls ◽

Breast Cancer Patients ◽

Female Patients ◽

Significant Difference ◽

Angiopoietin 2

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p < 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p > 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p > 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.

Download Full-text